Date: 2017-01-30
Type of information: Nomination
Compound: chief operating officer, chief medical officer, vice president finance
Company: Elsalys Biotech (France)
Therapeutic area: Cancer - Oncology - Ophtalmological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 30, 2017, ElsaLys Biotech announced that the company has strengthened its management team. Catherine Mathis, Liliane Bronstein and David Liens, join ElsaLys Biotech as chief operating officer, vice president finance and chief medical officer, respectively.
- Catherine Mathis, chief operating officer, has over 25 years’ experience in clinical research and regulatory affairs in the pharmaceutical and biotech industries, particularly in the fields of immunology and oncology.
- Liliane Bronstein, vice president finance, brings to ElsaLys Biotech solid experience in executive management and over 20 years’ financial experience within high growth innovative companies.
- Finally, David Liens, chief medical officer, brings more than 20 years’ experience in the field of drug development and medical affairs in large pharmaceutical groups and biotech growth companies.
Financial terms:
Latest news:
Is general: Yes
